Company news
Acrux Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Acrux receives $1.73m advance on FY25 R&D Tax Incentive
April 2, 2025
Investor Presentation February 2025
February 25, 2025
Appendix 4D and December 2024 Half Year Accounts
February 25, 2025
Acrux CEO announces plan to retire
February 6, 2025
Monthly Activities/Appendix 4C Cash Flow Report
January 29, 2025
Launch of 90 gram pack size of Dapsone 5%, Gel in US
January 15, 2025
Acrux raises $1.34 million from SPP
December 22, 2024
Investor Deck update, SPP Closes 18 December 2024, 5pm
December 17, 2024
Commercialisation of Nitroglycerin Ointment
December 12, 2024
Share Purchase Plan Offer Booklet
December 5, 2024
Investor Presentation
December 5, 2024
Share Placement successfully concluded and SPP launched
December 4, 2024
FDA Approval - Nitroglycerin Ointment
December 3, 2024
Trading Halt
December 2, 2024
AGM Presentation
November 20, 2024
FY24 R&D Tax Incentive rebate received
October 1, 2024
ASX Small and Mid Cap Conference presentation
September 23, 2024
FY24 Full Year Results - Investor Presentation
August 29, 2024
Appendix 4E and FY24 Full Year Statutory Accounts
August 29, 2024
FDA Approval received for Dapsone Gel, 7.5%
August 26, 2024
Quarterly Activities Report and Appendix 4C - June 2024
July 25, 2024
Acrux presentation to Bioshares, 18th Biotech Summit
July 14, 2024
RDTI funding facility secured
June 27, 2024
Acrux presentation at Hidden Gems in Lifesciences Forum
June 12, 2024
Launch of Dapsone 5%, Gel in the United States
April 2, 2024
Investor Presentation Half Year Accounts
February 27, 2024
Appendix 4D and Half Year Accounts
February 27, 2024
Appendix 4C and Activities Statement
January 30, 2024
Address of Chair and CEO to AGM
November 28, 2023
Acrux receives $2.88m R&D Tax Incentive Rebate for FY23
November 7, 2023
Investor Presentation - Acrux FY23 Results
August 24, 2023
Appendix 4E and FY23 Annual Report
August 24, 2023
Activities Statement and Appendix 4C
July 26, 2023
Acruxs seventh generic dossier accepted by FDA for review
July 3, 2023
4th FDA ANDA approval received - Dapsone Gel, 5%
June 7, 2023
Appendix 4D and Half Year Report
February 23, 2023
Quarterly Activities / Appendix 4C Cashflow Report
January 29, 2023
Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
January 22, 2023
Launch of prilocaine and lidocaine cream in United States
December 20, 2022
Mutual Termination of Co-Development Agreement
December 15, 2022
Chairman and CEO address to AGM
November 22, 2022
Remaining balance of R&D Tax Incentive Rebate received
October 2, 2022
Appendix 4E and FY22 Annual Report
August 25, 2022
Acruxs sixth generic dossier accepted by FDA for review
August 7, 2022
Acrux announces commercial agreement with Padagis
June 20, 2022
Successful patent litigation outcome
May 29, 2022
Appendix 4D, Half Year Accounts as at 31 December 2021
February 24, 2022
Acrux and Harris terminate license agreement
October 10, 2021
Acruxs fifth generic dossier accepted by FDA for review
September 12, 2021
Acrux Investor Presentation - September 2021
September 1, 2021
Decks
The 5 newest of 62 decks. Every deck is listed under its year.
- Investor Presentation (August 2026)
Investor deck · 26 slides · Aug 6, 2026
- Corporate Update (April 2026)
Corporate update · 18 slides · April 2026
- Shareholder Meeting (November 2025)
Shareholder meeting · 15 slides · Nov 25, 2025
- Investor Presentation (February 2025)
Investor deck · 19 slides · Feb 25, 2025
- Investor Presentation (December 2024)
Investor deck · 22 slides · Dec 17, 2024